Ovid stock: buy or sell?

OVID stock price: $5.85 14.93% At close on May 22nd, 2020

Updated on:
May 22nd, 2020

2

Ovid Therapeutics shares skyrocketed 14.93% to $5.85 on Friday. Friday was the fifth climbing day in a row, gaining 42.34%.

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States.

Should I buy Ovid stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best time to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Check the only buy setup that matches with Ovid stock now:

Buy setupElegible
New all-time highNo
New 52 week highYes
Price crossing up 200d MANo
100d MA crossing up 200d MANo

Is Ovid Therapeutics stock a buy?

Financial institutions and banks publish stock ratings everyday. Unfortunately, we couldn't find any rating for OVID stock for the last 30 days.

Ovid stock analysis

Daily outlook

Shares of Ovid skyrocketed an outstanding 14.93% and closed at $5.85.

Ovid skyrocketed an outstanding 14.93% and closed at $5.85. Since price and SMA200d lines crossed up on April/13, OVID climbed $3.01 (105.99%). From a daily perspective, OVID is in a short term uptrend after plotting its last bottom ($3.25, on May 1st) higher than the previous bottom, and its last top ($4.48, on May 13th) also over the previous top. Now trading in between its last bottom and last top OVID might consolidate in a plain range, waiting to break out over $4.48 or down under $3.25.

OVID stock chart (daily)

Weekly outlook

Shares of Ovid closed this week at $5.85 and boosted an astounding 42.34%. Last week was the 3rd green week in a row.

Since price and SMA40w lines crossed up by mid April, OVID climbed $3.01 (105.99%). By mid October 2019, SMA20w and SMA40w crossed up triggering a rise of 155.46%.

OVID stock chart (weekly)

Ovid stock price history

Ovid stock went public on May 5th, 2017 with a price of $14.001. Since then, OVID stock sliced a -58.20%, with a yearly average of -19.40%.

1: Adjusted price after possible price splits or reverse-splits.

Ovid stock historical price chart

OVID stock reached 52-week highs on Friday at $6.11, and all-time highs 2017-05-18 with a price of 15.93.

Ovid stock price target

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we have not detected any price forecast for Ovid Therapeutics stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

, Ovid failed to meet the estimates of the experts and reported a bad EPS of $-0.52 per share when experts were expecting $-0.55.
OVID earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/an/an/a
2017-Q2-n/an/an/a
2017-Q3-n/an/an/a
2017-Q42018-03-29-0.39-0.45n/a
2018-Q12018-05-08-0.48-0.54n/a
2018-Q22018-08-09-0.59-0.53n/a
2018-Q32018-11-08-0.59-0.53n/a
2018-Q42019-03-07-0.55-0.52n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

In , Ovid annual revenues to million dollars from marked in . , its income margin (compared to sales) to , that is million.

OVID annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY

Quarterly financial results

Reported quarter income marked $-12.90 M with a profit margin of . Profit margin remained steady a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Ovid sales marked a tight move and stayed stable a nan%. Looking back to recent quarterly results, Ovid Therapeutics posted 7 positive quarters in a row.
OVID quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2

Ovid ownership

When you are planning to buy a company, it's worth to check its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Ovid, 41.03% of all outstanding shares are owned by its staff.

In case of Ovid Therapeutics stock, 33.28% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for OVID stock account 0.00%, no big difference from last month.

For a better understanding, the next table shows ownership data compared to other related companies:

OVID
Market cap$320.3 M
Total shares54.8 M
Float shares32.3 M
  - Institutional holdings (%)33.3%
  - Insider holdings (%)41.0%
Shares in short selling0.0%

Ovid summary

Friday, May 22nd, 2020
Open$5.15
Close$5.85
Day range$5.15 - $6.11
Previous close$5.09
Session gain14.93%
Average true range$0.46
50d mov avg$3.33
100d mov avg$3.47
200d mov avg$3.14
Daily patternlt06a
Weekly pattern

Ovid performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We compared Ovid Therapeutics against in the following table:
Stock3m6m12m
OVIDOvid Therapeutics65.25%108.93%244.12%

Ovid competitors

Unfortunately, we could not find any public company that could be defined as Ovid competitor. This doesn't mean Ovid does not have any competitor in the market, it's just we could not detected it.